Our Pipeline

Our integrative discovery approach combines functional screening with an effect-driven research approach to advance programs in immunology and immuno-oncology.

​

For cancer, our pipeline holds a first-in-class immune activator, that can help to target a wide range of challenging malignancies,  has synergies with checkpoint inhibitors, and the potential for monotherapy. 

​

Our small molecule drug candidates differentiate themselves through their unique safety profile and better drug-like properties with oral bioavailability and efficient tissue penetration.​